SCHEMBL17248015

SCHEMBL17248015

Cc1cnc(C2CC2)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.45
NOS1 P29475 1/20 0.45
NOS2 P35228 1/20 0.45
PDK2 Q15119 1/20 0.37
PDK4 Q16654 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HTT P42858 1/20 0.36
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
CCR8 P51685 1/20 0.35
CHRM4 P08173 1/20 0.33
SMO Q99835 1/20 0.33
SSTR4 P31391 1/20 0.33
CYP1A2 P05177 1/20 0.32
CHRM5 P08912 2/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12250792 0.92 NOS3 (0.42) NOS3NOS1NOS2PDK2PDK4
SCHEMBL20135330 0.87 HTR2C (0.42) NOS3NOS1NOS2CHRM4SSTR4
SCHEMBL20135134 0.80 TRPC6 (0.39) CHRM4SMOSSTR4PDE10A
SCHEMBL14910572 0.79 NOS3 (0.34) NOS3NOS1NOS2KDM4EHTT
SCHEMBL16132537 0.79 L3MBTL1 (0.38) KDM4EHTTCHRM4OPRL1CNR2
SCHEMBL29989036 0.79 OPRL1 (0.40) NOS3NOS1NOS2PDK2PDK4
SCHEMBL15599220 0.79 OPRL1 (0.40) NOS3NOS1NOS2PDK2PDK4
SCHEMBL29989564 0.79 PDK2 (0.36) NOS3NOS1NOS2PDK2PDK4
SCHEMBL2470465 0.75 NOS3 (0.38) NOS3NOS1NOS2PDK2PDK4
SCHEMBL18635770 0.75 OPRL1 (0.34) CHRM4OPRL1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018029288-A1 SULFONYL PYRIDYL TRP INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-02-15 WO disclosed
US-9550775-B2 Substituted triazolopyridines and methods of use thereof GENENTECH, INC. (US) 2017-01-24 US disclosed
US-9493429-B2 Substituted benzoxazoles and methods of use thereof GENENTECH, INC. (US) 2016-11-15 US disclosed
US-20160264567-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS GENENTECH, INC. (US) 2016-09-15 US disclosed
WO-2016128529-A1 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2016-08-18 WO disclosed
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2016-01-14 US disclosed
US-20160009667-A1 SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-01-14 US disclosed
US-20150322002-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322002-A1 N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, SNRPD2, RDX NOS3 1021/4885NOS1 1122/4885NOS2 1019/4885
US-20160009710-A1 SUBSTITUTED TRIAZOLOPYRIDINES AND METHODS OF USE THEREOF P2RX3, P2RX1, P2RX4 NOS3 920/4885NOS1 1582/4885NOS2 1375/4885
US-20160009667-A1 SUBSTITUTED BENZOXAZOLES AND METHODS OF USE THEREOF CYP4X1, BRIX1, HAX1 NOS3 2028/4885NOS1 2792/4885NOS2 2812/4885
US-20160264567-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS TRPA1, TRPV1, TRPV5 NOS3 776/4885NOS1 1007/4885NOS2 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.